文献速递耳科与耳神经

听力表型精准分型与感音神经性听力损失的基因发现

Precision Phenotyping With Audiometric Data and Gene Discovery for Sensorineural Hearing Loss.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2026-10-08

该遗传关联研究比较了基于听力图纯音平均(PTA)的精准表型与基于诊断编码的表型在感音神经性听力损失(SNHL)遗传发现中的效力。PTA-GWAS 识别出 3 个全基因组显著位点映射至 4 个基因(EML6、SPTBN1、ARHGEF28、EYA4),基于 SNP 的遗传力估计为 11.78%,而 ICD-GWAS 未发现显著位点且遗传力仅 2.90%。在 All of Us 队列中,PTA 衍生的多基因风险评分与自报耳聋显著相关(OR 1.09,95%CI 1.07-1.12),而 ICD 衍生评分无显著关联。

要点

  • 基于听力图 PTA 的定量表型较诊断编码表型能更有效发现 SNHL 相关基因位点
  • PTA-GWAS 遗传力估计为 11.78%,显著高于 ICD-GWAS 的 2.90%
  • PTA 衍生多基因风险评分在独立队列中与自报耳聋显著相关

核心结论

  • 使用听力图 PTA 的精准表型较基于诊断编码的方法改善了 SNHL 的遗传发现。
  • 更高的遗传力估计、全基因组显著位点的识别及更强的多基因风险估计表明定量听力测量能更好地捕捉遗传架构。

研究设计与样本

  • 遗传关联研究,利用单中心三级生物样本库中欧洲遗传 ancestry 人群的全基因组测序数据开展两项独立 GWAS。
  • 第一项 GWAS 基于 ICD-9/ICD-10 诊断与操作编码定义病例与对照,纳入 10 164 例病例(平均年龄 63.9 岁,女性 50.4%)和 51 305 例对照(平均年龄 51.1 岁,女性 56.1%)。
  • 第二项 GWAS 采用精准表型,以较好耳的标准三频率 PTA 作为连续变量,纳入 16 057 名有 PTA 数据的参与者(平均年龄 55.5 岁,女性 57.0%)。
  • 数据分析时间为 2025 年 8 月至 2026 年 4 月。

主要发现

  • 基于 PTA 的 GWAS 识别出 3 个全基因组显著位点,映射至 4 个基因:EML6、SPTBN1、ARHGEF28、EYA4(基于 SNV 的遗传力估计 h2 = 11.78%;SE = 2.84%)。
  • 基于 ICD 的 GWAS 未识别出显著位点(h2 = 2.90%;SE = 0.77%)。
  • PTA 基于 GWAS 与 3 个听力相关能力性状存在全基因组相关性(例如 PTA-GWAS 与助听器使用:r = 0.985;SE = 0.163;P = 1.56 × 10-9)。
  • 在 All of Us 队列中,PTA 衍生的多基因风险评分与自报耳聋显著相关(OR 1.09;95%CI 1.07-1.12),而 ICD 衍生评分无显著关联(OR 1.00;95%CI 0.97-1.02)。

临床怎么用

  • 在耳鼻咽喉科遗传研究与精准医学实践中,应优先采用听力图 PTA 等定量听力学指标定义 SNHL 表型,而非仅依赖诊断编码。
  • PTA 衍生的多基因风险评分可用于独立队列中自报耳聋的风险分层评估。

局限性

  • 研究基于欧洲遗传 ancestry 人群的单中心生物样本库数据,外推至其他 ancestry 人群需谨慎。
  • ICD 编码表型依赖诊断与操作编码的准确性,可能引入错分偏倚。
  • All of Us 队列中的耳聋结局为自报,非听力学确诊。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The genetic architecture underlying hearing sensitivity as a quantitative trait is critical for advancing precision medicine in hearing health. Despite extensive genome-wide association study (GWAS) efforts, few strong genetic drivers have been identified. OBJECTIVE: To compare the sensitivity for detecting genetic variants associated with sensorineural hearing loss (SNHL) using precision phenotyping with pure-tone averages (PTAs) with common phenotyping using diagnostic coding approaches. DESIGN, SETTING, AND PARTICIPANTS: In this genetic association study, 2 separate GWASs were conducted using different phenotyping approaches for SNHL: (1) diagnostic code control and (2) precision phenotyping with PTA data. Whole-genome sequencing data from a population with European genetic ancestry collected at a single tertiary center biobank was used. For the control GWAS based on diagnostic codes, case and control participants were defined using primarily International Classification of Diseases, Ninth Revision (ICD-9) and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) diagnosis and procedure codes related to SNHL hearing loss. For the precision phenotyping GWAS, hearing status was defined as a continuous variable, using the standard 3-frequency PTA of the better hearing ear from the audiogram. Data analysis was conducted from August 2025 to April 2026. MAIN OUTCOMES AND MEASURES: GWAS summary statistics were used to calculate estimates of single-nucleotide variant (SNV)-based heritability for PTA and ICD phenotypes; to map the genetic risk loci to candidate genes using functional annotation; to evaluate genetic correlations with existing GWASs; and to calculate polygenic risk scores for testing in an independent cohort from the National Institutes of Health's All of Us Research Program. RESULTS: Overall, 10 164 case participants (mean [SD] age, 63.9 [21.3] years; 5118 [50.4%] female) and 51 305 control participants (mean [SD] age, 51.1 [21.0] years; 28 784 [56.1%] female) were included in the first GWAS; 16 057 participants with PTA (mean [SD] age, 55.5 [21.8] years; 9147 [57.0%] female) were included in the second GWAS. PTA-based GWAS identified 3 genome-wide significant loci mapped to 4 genes: EML6, SPTBN1, ARHGEF28, and EYA4 (SNV-based heritability estimate [h2] = 11.78%; SE = 2.84%). ICD-based GWAS identified no significant loci (h2 = 2.90%; SE = 0.77%). Genome-wide correlations between the PTA-based GWAS and 3 hearing-related ability traits were found (eg, PTA-based GWAS and hearing aid use: r = 0.985; SE = 0.163; P = 1.56 × 10-9). In the All of Us cohort, PTA-derived polygenic risk scores were significantly associated with self-reported deafness (odds ratio [OR], 1.09; 95% CI, 1.07-1.12), whereas ICD-derived scores were not (OR, 1.00; 95% CI, 0.97-1.02). CONCLUSIONS AND RELEVANCE: In this genetic association study, precision phenotyping using audiometric PTAs improved genetic discovery for SNHL compared with diagnostic code-based approaches. Higher heritability estimates, identification of genome-wide significant loci, and stronger polygenic risk estimation indicate that quantitative hearing measures better capture genetic architecture, supporting precision medicine in hearing health.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. DeFreese AJ, Rubat du Mérac T, Sheng Q, et al. Precision Phenotyping With Audiometric Data and Gene Discovery for Sensorineural Hearing Loss. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 42848395. doi:10.1001/jamaoto.2026.3089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。